← Pharmacy curriculum
Module 629 lessons2024 international hyperglycemic-crises consensus and ADA Standards of Care 2026

Diabetic Ketoacidosis

Recognize, stabilize, treat, monitor, resolve, and prevent diabetic ketoacidosis through ketone-centered diagnosis and coordinated fluid, electrolyte, insulin, and transition care.

01

Explain how insulin deficiency and counterregulatory stress produce ketonemia and metabolic acidosis.

02

Diagnose DKA using glucose or diabetes history, ketones, and acidosis without excluding euglycemic presentations.

03

Sequence fluids, potassium, insulin, and dextrose from hemodynamic and laboratory data.

04

Calculate anion gap, corrected sodium, effective osmolality, fluid rates, insulin rates, and electrolyte replacement.

05

Identify treatment complications, special populations, resolution, and safe transition to subcutaneous insulin.

06

Investigate the precipitating cause and construct a practical recurrence-prevention plan.

62.01

Insulin Deficiency and Ketone Biology

DKA develops when insulin is insufficient for metabolic needs and counterregulatory signals accelerate glucose production, lipolysis, ketogenesis, osmotic diuresis, and electrolyte loss.

What to learn
  • Absolute and relative deficiency
  • Counterregulatory hormones
  • Lipolysis
  • Ketogenesis
  • Osmotic diuresis
Metabolic cascadeInsulin deficiency becomes ketone acidosis
01ReleaseCounterregulatory stress

Increase hepatic glucose and adipose lipolysis

02ConvertFree fatty acids

Generate beta-hydroxybutyrate and acetoacetate

03LoseOsmotic diuresis

Deplete water, sodium, potassium, and phosphate

Connect insulin deficiency to ketones

Insufficient insulin and increased glucagon, catecholamines, cortisol, and growth hormone activate lipolysis. The liver converts free fatty acids to ketone bodies, especially beta-hydroxybutyrate, while hepatic glucose production rises and peripheral glucose use falls.

Connect glucose to volume loss

Hyperglycemia causes glucosuria and osmotic diuresis, producing water, sodium, potassium, phosphate, and magnesium deficits. Vomiting and reduced intake deepen the deficit. Serum potassium can initially appear normal or high despite substantial total-body depletion.

Connect acid to compensation

Accumulating ketoacids consume bicarbonate and produce high-anion-gap metabolic acidosis. Respiratory compensation creates deep rapid breathing. Acetone can produce fruity breath, while nausea, vomiting, abdominal pain, dehydration, and cognitive change reflect systemic illness rather than a gastrointestinal diagnosis alone.

0 of 1 answered
01Why can serum potassium be high when total-body potassium is depleted in DKA?
Answer every question to submit.
62.02

Diagnosis, Ketone Measurement, and Severity

Current diagnosis requires diabetes or qualifying hyperglycemia, elevated ketones, and metabolic acidosis, with all three components established.

What to learn
  • Three-part criteria
  • Beta-hydroxybutyrate
  • Euglycemic DKA
  • Venous pH
  • Severity
Three-part diagnosisConfirm glucose or diabetes, ketones, and acidosis
01DDiabetes or glucose

History of diabetes or glucose at least 200 mg/dL

02KKetonemia

Beta-hydroxybutyrate at least 3.0 mmol/L

03AAcidosis

Venous pH below 7.3 or bicarbonate below 18

Apply the three criteria

DKA requires glucose at least 200 mg/dL or a prior history of diabetes, beta-hydroxybutyrate at least 3.0 mmol/L or sufficiently positive urine ketones, and metabolic acidosis with venous pH below 7.3 and/or bicarbonate below 18 mmol/L. A single elevated anion gap is not the complete diagnosis.

Measure the ketone that matters

Blood beta-hydroxybutyrate is preferred because urine nitroprusside testing detects acetoacetate rather than the dominant beta-hydroxybutyrate. Urine ketones can underestimate early DKA and appear to worsen during recovery as beta-hydroxybutyrate converts back to acetoacetate.

Do not require extreme glucose

Euglycemic DKA has glucose below 200 mg/dL with ketonemia and acidosis. Reduced intake, pregnancy, alcohol, liver failure, exogenous insulin, and SGLT2 inhibitors are important contexts. Severity and care setting depend on acidosis, ketonemia, mental status, comorbidity, and monitoring capacity.

0 of 1 answered
01A patient taking an SGLT2 inhibitor has glucose 176 mg/dL, beta-hydroxybutyrate 4.2 mmol/L, and venous pH 7.22. What is the best interpretation?
Answer every question to submit.
62.03

Precipitating Causes and Differential Diagnosis

DKA treatment is incomplete until the cause of insulin deficiency, increased demand, or both has been identified and addressed.

What to learn
  • Missed insulin
  • Pump failure
  • Infection
  • SGLT2 inhibitors
  • Alternative ketoacidosis
Trigger investigationFind why insulin became insufficient
01DeliveryInsulin interruption

Missed dose, access, technique, pump, or infusion set

02DemandAcute stress

Infection, ischemia, trauma, surgery, or pregnancy

03Drug and contextEuglycemic risk

SGLT2 inhibitor, fasting, alcohol, or low intake

Find interrupted insulin

New type 1 diabetes, missed or unaffordable insulin, incorrect dosing, pump or infusion-set failure, and inadequate sick-day adjustment are common mechanisms. A pump user can develop ketosis quickly because no long-acting depot remains.

Find increased metabolic demand

Infection, myocardial infarction, stroke, pancreatitis, trauma, surgery, glucocorticoids, sympathomimetics, immune checkpoint inhibitor diabetes, and pregnancy can increase insulin needs or reveal insulin deficiency. Search should follow symptoms and risk rather than automatic broad testing alone.

Distinguish other ketone states

Starvation ketosis, alcoholic ketoacidosis, toxic alcohol exposure, lactic acidosis, kidney failure, and mixed disorders can overlap. Diabetes history does not make every anion-gap acidosis DKA, and a normal glucose does not exclude DKA.

0 of 1 answered
01What should be investigated immediately in a pump user with new DKA?
Answer every question to submit.
62.04

Fluid Resuscitation and Osmolality

Fluids restore circulating volume, renal perfusion, ketone clearance, and insulin sensitivity while requiring careful attention to sodium, osmolality, heart failure, and kidney disease.

What to learn
  • Isotonic resuscitation
  • Balanced crystalloids
  • Corrected sodium
  • Osmolality
  • Volume-sensitive patients
Fluid strategyRestore perfusion while controlling osmotic change
01ResuscitateIsotonic crystalloid

Restore circulating volume and kidney perfusion

02ReassessSodium and osmolality

Interpret expected shifts as glucose falls

03IndividualizeLimited reserve

Use smaller increments in heart or kidney failure

Restore perfusion first

In adults without cardiac or kidney compromise, isotonic saline or a balanced crystalloid is commonly given at 500 to 1,000 mL/h during the first 2 to 4 hours. Reassess blood pressure, pulse, perfusion, sodium, urine output, and fluid balance rather than running a fixed rate without review.

Interpret sodium during glucose decline

As glucose falls, water shifts intracellularly and measured sodium may rise. An expected early sodium rise is not by itself an indication for hypotonic fluid. Effective osmolality and its rate of decline, corrected sodium, hydration, and response guide subsequent fluid selection.

Reduce intensity when reserve is limited

Older adults and people with heart failure or end-stage kidney disease may require smaller boluses such as 250 mL with frequent hemodynamic assessment. Balanced crystalloids may reduce hyperchloremic acidosis and can shorten recovery in some studies.

0 of 1 answered
01Measured sodium rises modestly as glucose falls after initial fluids, while osmolality is declining appropriately. What is the best response?
Answer every question to submit.
62.05

Potassium, Phosphate, and Electrolyte Safety

Potassium management determines when insulin can safely start and must anticipate the rapid intracellular shift produced by treatment.

What to learn
  • Total-body deficit
  • Insulin delay threshold
  • Replacement
  • Phosphate
  • Monitoring
Electrolyte gatePotassium determines when insulin can begin
01Below 3.5Replace first

Delay insulin until potassium is safe

02Below 5.0Add replacement

Maintain a target of 4 to 5 mmol/L

03After insulinMeasure repeatedly

Recheck early, then at least every four hours

Sequence potassium before insulin

If potassium is below 3.5 mmol/L, begin replacement and delay insulin until potassium exceeds 3.5 to reduce arrhythmia and respiratory-muscle risk. Once potassium falls below 5.0 mmol/L, replacement is generally added to fluids to maintain 4 to 5 mmol/L.

Replace and monitor dynamically

For many adults, 20 to 30 mmol of potassium per liter of fluid maintains the target, but kidney function, urine output, ECG findings, acid-base change, and repeated concentrations govern the actual plan. Recheck potassium about 2 hours after insulin starts and at least every 4 hours until resolution.

Use phosphate selectively

Routine phosphate replacement does not improve DKA outcomes and can cause hypocalcemia. Consider replacement when phosphate is below 1.0 mmol/L with respiratory or cardiac compromise or clinically important muscle weakness, using monitored potassium phosphate when appropriate.

0 of 1 answered
01A patient with DKA has potassium 3.1 mmol/L. What should happen before insulin infusion?
Answer every question to submit.
62.06

Insulin, Dextrose, and Subcutaneous Treatment

Insulin stops ketogenesis, while dextrose permits insulin to continue after glucose improves until ketoacidosis resolves.

What to learn
  • IV regular insulin
  • Fixed rate
  • Dextrose threshold
  • Subcutaneous pathway
  • Bicarbonate
Ketone clearanceInsulin continues after glucose improves
01Start0.1 units/kg/h

Stop ketogenesis after potassium safety

02AddDextrose below 250

Prevent hypoglycemia while insulin continues

03Reduce0.05 units/kg/h

Maintain glucose near 200 until resolution

Stop ketogenesis with insulin

A fixed-rate IV short-acting insulin infusion of 0.1 units/kg/h is standard for DKA. An IV or IM bolus is generally reserved for an anticipated delay in venous access rather than routine use before every infusion.

Add glucose before the acidosis is resolved

When glucose falls below 250 mg/dL, add 5 to 10 percent dextrose and reduce the infusion toward 0.05 units/kg/h, maintaining glucose near 200 while ketones and acidosis clear. Stopping insulin because glucose normalizes can cause persistent or recurrent ketoacidosis.

Select alternative pathways carefully

Mild or moderate uncomplicated DKA can be treated with subcutaneous rapid-acting analogs every 1 to 2 hours in settings with validated protocols and intensive monitoring. Routine bicarbonate is not recommended and is generally reserved for severe acidosis with pH below 7.0.

0 of 1 answered
01Why is dextrose added when glucose falls below 250 mg/dL during DKA treatment?
Answer every question to submit.
62.07

Monitoring, Acid-Base Interpretation, and Resolution

DKA resolves when ketonemia and acidosis resolve, not merely when glucose or the anion gap appears normal.

What to learn
  • Hourly glucose
  • Four-hour chemistry
  • Beta-hydroxybutyrate
  • Hyperchloremic acidosis
  • Resolution criteria
Resolution dashboardFollow ketones and acid-base recovery
01HourlyGlucose

Check every one to two hours

02Four-hourChemistry and ketones

Trend electrolytes, pH, creatinine, and beta-hydroxybutyrate

03ResolveKetones plus pH

Use beta-hydroxybutyrate below 0.6 and pH or bicarbonate recovery

Monitor the treatment system

Check capillary glucose every 1 to 2 hours. Measure electrolytes, phosphate, creatinine, beta-hydroxybutyrate, and venous pH about every 4 hours until DKA resolves, with potassium checked about 2 hours after insulin begins. Track neurologic status, hemodynamics, intake, output, and cumulative fluids.

Do not mistake chloride for persistent ketones

Large chloride exposure and urinary loss of ketoanions can produce non-anion-gap hyperchloremic acidosis during recovery. The anion gap can therefore misrepresent resolution. Urine ketones can remain positive as beta-hydroxybutyrate converts to acetoacetate.

Use current resolution criteria

Resolution is plasma beta-hydroxybutyrate below 0.6 mmol/L plus venous pH at least 7.3 or bicarbonate at least 18 mmol/L. Glucose should ideally be below 200 mg/dL. Do not end treatment from glucose or anion gap alone.

0 of 1 answered
01Glucose is 168 mg/dL and the anion gap is closed, but beta-hydroxybutyrate is 1.4 mmol/L. Is DKA resolved?
Answer every question to submit.
62.08

Treatment Complications and Special Populations

Hypoglycemia, hypokalemia, cerebral injury, thrombosis, pulmonary edema, kidney injury, and overly rapid osmotic change are preventable treatment hazards.

What to learn
  • Hypoglycemia
  • Hypokalemia
  • Cerebral edema
  • Fluid overload
  • Pregnancy and SGLT2
Treatment safetyPrevent harm while reversing the crisis
01GlucoseHypoglycemia

Add dextrose and adjust insulin

02PotassiumArrhythmia and weakness

Replace before and during insulin

03VolumeOverload or osmotic injury

Adjust fluids to age, heart, kidney, and neurologic risk

Prevent common treatment harm

Add dextrose before hypoglycemia, reduce insulin without stopping ketone clearance, and replace potassium proactively. Hyperchloremic acidosis is often self-limited, while severe hypoglycemia and hypokalemia are associated with greater mortality.

Protect vulnerable physiology

Children and adolescents require pediatric protocols because cerebral injury risk, fluid strategy, and dosing differ. Pregnancy can produce DKA at lower glucose and threatens both pregnant patient and fetus. Heart failure and dialysis require smaller fluid increments and frequent reassessment.

Recognize drug-associated euglycemic DKA

Stop the SGLT2 inhibitor and treat ketoacidosis based on ketones and acid-base status rather than waiting for marked hyperglycemia. Investigate fasting, surgery, dehydration, insulin reduction, low-carbohydrate intake, alcohol, and infection.

0 of 1 answered
01Which feature most changes initial fluid management in an older adult with DKA and end-stage kidney disease?
Answer every question to submit.
62.09

Transition, Discharge, and Recurrence Prevention

Resolution begins the prevention phase: insulin overlap, medication reconciliation, trigger correction, access, education, ketone tools, and rapid follow-up.

What to learn
  • Basal overlap
  • Cause correction
  • Access
  • Sick-day plan
  • Follow-up
Prevention bridgeResolution is followed by reliable access and action
01OverlapBasal insulin

Activate subcutaneous coverage before IV insulin stops

02CorrectPrecipitating cause

Treat illness, device, access, and medication failures

03EquipSick-day plan

Provide insulin, ketones, hydration, rescue, and follow-up

Overlap subcutaneous insulin

Administer basal insulin before stopping IV insulin, commonly with 1 to 2 hours of overlap according to the selected product and protocol. Calculate the outpatient dose from preadmission therapy, recent IV needs, nutrition, kidney function, hypoglycemia risk, and the reason the prior plan failed.

Correct the precipitating system

Treat infection or ischemia, replace failed pump supplies, correct technique, reconcile concentrated insulin and devices, reassess SGLT2 therapy, and address missed insulin without blame. Cost, housing, food, transportation, mental health, substance use, and eating disorders can be direct recurrence mechanisms.

Teach a usable prevention plan

Provide written sick-day insulin, hydration, glucose, blood or urine ketone, correction, emergency, and contact instructions. Basal insulin should not be stopped simply because the person is not eating. Ensure insulin, needles, monitoring, glucagon, ketone supplies, and timely follow-up are physically available.

0 of 1 answered
01What prevents a coverage gap when transitioning off an IV insulin infusion?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 100 question bank.

100 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. 2024 international consensus on hyperglycemic crises
  2. ADA 2026 glycemic goals, hypoglycemia, and hyperglycemic crises
  3. ADA 2026 diabetes care in the hospital
PharmacyOpen tools